CAN-1012 SR is under clinical development by CanWell Pharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CAN-1012 SR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CAN-1012 SR overview

CAN-1012 is under development for the treatment of advanced metastatic solid tumors, melanoma, merkel cell carcinoma, metastatic breast cancer, metastatic renal cell carcinoma, head and neck cancer squamous cell carcinoma, sarcomas, transitional cell cancer (urothelial cell cancer), vulvar cancer, vaginal cancer, penile cancer, cervical cancer and metastatic colorectal cancer. It is administered through intratumor route as injection. The therapeutic candidate is sustained release formulation and acts by targeting TLR7.

For a complete picture of CAN-1012 SR’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.